PulmoBREATHE - the double power from the cough!

Composition of active ingredients: 

1 sachet or 1 coated tablet contains -
acetylcysteine 200 mg, ambroxol hydrochloride 30 mg

Dosage form: 

2 g of powder in a sachet, 10 or 20 sachets in a carton package.
20 tablets in a blister, 1 or 2 blisters in carton package.

  • Unique* combination of the active ingredients in Ukraine
    recognized by pulmonologists all over the world*.
  • Copes with cough faster than mono preparations
    (ambroxol or acetylcysteine)*
  • Reduces intoxication and provides antioxidant action
Indications: 
Adults
Children from 12 years

Administration and Dosages

Sachet: to dissolve the content of 1 sachet in a half - glass of water. Dose for adults and children older than 12 years:  take 1 sachet 3 times per day.

Tablets: adults and children over 12 years - 1 tablet 3 times a day.

Do not take more than recommended dose. Do not take more than 5-7 days without asking your doctor.

Pharmacotherapeutic group

Medicine for cold and flu treatment. Mucolytic ingredients. Combinations. The R05C ATX 10.

Pharmacological properties

Ambroxol hydrochloride – mucolytic, expectorant ingredient with a strong expectorant, anti-inflammatory, immunomodulatory, anti-oxidant and a slight antitussive effect. It stimulates serous cells of glands of bronchial mucosa, increases the amount of mucous secretion, and thus changes the disturbed ratio of serous and mucous components. Normalizing sputum rheology, reducing its viscosity and adhesive properties.
Directly stimulating the motor activity of ciliated epithelium of bronchi, prevents its sticking and improves mucociliary phlegm evacuation. Ambroxol increases the concentration of surfactant in the lungs and prevents its destruction in pneumocytes.

Ambroxol does not cause bronchial obstruction, but rather improves the respiratory function. It is proved that the drug reduces muscle hyperreactivity of the bronchi of patients with asthma. Ambroxol has anti-inflammatory effect, antioxidant properties, stimulates local immunity and the resumption of natural surfactant layer. Reducing cough and phlegm significantly.

Acetylcysteine ​​- mucolytic and expectorant. Due to a free sulfhydryl group communication bursts bisulfide mucopolysaccharides mucus, which leads to a decrease in the viscosity of the bronchial secretion. It increases mucociliary clearance. It has antioxidant effects due to the properties to bind free radicals. It increases the synthesis of glutathione, which is an important factor in the detoxification; Due to this property Acetylcysteine ​​used for the treatment of acute poisoning with paracetamol, phenols, aldehydes, and other substances.    

To obtain full information please see the Patient Leaflet Information. 

Indications

The acute and the chronic respiratory diseases treatment, which are accompanied by a violation of mucus and sputum secretion:

  • acute and chronic bronchitis;
  • chronic obstructive pulmonary disease;
  • pneumonia;
  • bronchiectasis;
  • asthma;
  • cystic fibrosis;
  • laryngitis;
  • tracheitis;
  • shock lung syndrome in adults;
  • the prevention of complications after lung surgery;
  • care of a tracheostomy;
  • before and after bronchoscopy.

Contraindications

Individual hypersensitiveness to ambroxol, acetylcysteine or other medicine ingredients.

To obtain full information please see the Patient Leaflet Information.

The  synergies acetylcysteine ​​with bronchodilators was Identified.

Acetylcysteine ​​reduces the hepatotoxicity of paracetamol; cysteine ​​can be a donor and increase the level of glutathione, which promotes detoxification of free radicals and toxic substances in the body.

The use of ambroxol increases the concentration of antibiotic amoxicillin, cefuroxime, erythromycin and doxycycline in the sputum and bronchopulmonary secretions. Together with the use of antibiotics such as tetracycline (except doxycycline), ampicillin, amfoterritsin V, cephalosporins, aminoglycosides may them reacting with the thiol group acetylcysteine, which may lead to reduced activity of the two medicines. Therefore, leave at least 2 hours between doses.  It does not apply to cefixime and loracarbef.

During contact with metal or rubber form sulfides with a characteristic odor, so the dissolution of the  medicine should be used glassware.

The product contains aspartame, which is a source of phenylalanine, and the medicine should not be used in patients with phenylketonuria.

The medicine  should not be used in the I trimester of pregnancy. There are no relevant data on the teratogenic effect of ambroxol hydrochloride and acetylcysteine on the fetus, therefore, to use the drug in the II- III trimester of pregnancy is possible only if the utility to the mother outweighs the potential risk to the fetus. Since acetylcysteine and ambroxol hydrochloride passes into breast milk, should not take the drug during lactation. During the administration of the drug is necessary to stop breastfeeding.

To obtain full information please see the Patient Leaflet Information.

Store in the original package below +25°С.
Keep out of the reach of children.

R.S.  MOH  of  Ukraine №  UA/10212/01/01; UA/10212/02/01 of 09.09.2014